ClinicalTrials.gg
CompletedNCT01068743Updated May 8, 2015Results posted

Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered

A Phase 1 interventional study of saxagliptin and metformin in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-08.

Sponsored by AstraZeneca · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. saxagliptin · Diabetes Mellitus, Type 2.

Enrollment
59th of 74
24 · median 138
Started
2010
with 5 others
Phase 1
14 of 74
none open now
Registered
24th of 74
by date
Lead sponsor
48 of 74
AstraZeneca

Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, this one is the 59th largest by enrollment, is one of 6 that started in 2010, is one of 14 in phase 1, and was the 24th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About saxagliptin

saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To demonstrate bioequivalence of a 2.5 mg saxagliptin/850 mg metformin fixed dose combination (FDC) tablet relative to the 2.5 mg saxagliptin tablet and 850 mg metformin (Glucophage Marketed by Merck-Serono) tablet co-administered to healthy subjects in the fasted and fed condition.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ages 18 to 55 inclusive
  • Healthy subjects as determined by no deviation from normal in medical history, physical examination, (ECGs), and clinical laboratory determinations
  • (BMI) of 18 to 32 kg/m\^2, inclusive. BMI = weight (kg)/ [height (m)]\^2

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness
  • Current or recent (within 3 months) gastrointestinal disease
  • Any major surgery within 4 weeks of study drug administration
  • History of allergy to a dipeptidyl peptidase-IV (DPP4) inhibitor or related compound
  • History of allergy or intolerance to metformin or other similar acting agents
  • Prior exposure to saxagliptin
  • Prior exposure to metformin within 3 months of study drug administration
  • Estimated (Clcr) of \< 80 mL/min using the Cockcroft Gault formula
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Other
    Arm A (saxagliptin 2.5 mg + metformin 850 mg; Fasting)

    A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fasted condition.

    Drug: saxagliptin · Drug: metformin

  • Other
    Arm B (saxagliptin 2.5 mg + metformin 850 mg FDC; Fasting)

    A single oral dose of 2.5-mg saxagliptin/850-mg metformin fixed dose combination (FDC) administered in the fasted condition.

    Drug: saxagliptin + metformin (FDC tablet)

  • Other
    Arm C (saxagliptin 2.5 mg + metformin 850 mg; Fed)

    A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fed condition.

    Drug: saxagliptin · Drug: metformin

  • Other
    Arm D (saxagliptin 2.5 mg + metformin 850 mg FDC; Fed)

    A single oral dose of 2.5-mg saxagliptin/850-mg metformin FDC administered in the fed condition.

    Drug: saxagliptin + metformin (FDC tablet)

Interventions

  • Tablets, Oral, 2.5 mg, once daily, single dose

    Also known as: Onglyza

  • Tablets, Oral, 850 mg, once daily, single dose

    Also known as: Glucophage

  • Drugsaxagliptin + metformin (FDC tablet)

    Drug pages: Saxagliptin · Metformin

    Tablet, oral, (saxagliptin 2.5 mg) (metformin 850 mg), once daily, single dose

06

What researchers measure

Primary outcomes

  1. Saxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

  2. Saxagliptin PK Parameter Observed Maximum Plasma Concentration (Cmax)

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

  3. Metformin PK Parameter AUC(0-inf)

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

  4. Metformin PK Parameter Cmax

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

Secondary outcomes

  1. 5-hydroxy Saxagliptin PK Parameter AUC(0-inf)

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

  2. 5-hydroxy Saxagliptin PK Parameter Cmax

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

  3. 5-hydroxy Saxagliptin PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\[0-t\] is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

  4. 5-hydroxy Saxagliptin PK Parameter Terminal Half-life (T 1/2)

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

  5. 5-hydroxy Saxagliptin PK Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax)

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

  6. Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs).

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

    Time frame: AEs: from study drug administration Day 1/Period 1 till study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or study participation. Duration of the study was approximately 45 days (including screening).

  7. Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities

    Abnormalities that were considered clinically significant and/or reported as an AE by the investigator.

    Time frame: From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).

Other outcomes

  1. Saxagliptin PK Parameter AUC(0-t)

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-t) is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

  2. Saxagliptin PK Parameter T1/2

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

  3. Saxagliptin PK Parameter Tmax

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

  4. Metformin PK Parameter AUC(0-t)

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-t) is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

  5. Metformin PK Parameter T1/2

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

  6. Metformin PK Parameter Tmax

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.

    Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing

07

Results

Posted Feb 8, 2012

Participant flow

Participants (N = 24) who met all of the inclusion and none of the exclusion criteria were recruited from a single site in the United States.

Period 1
Participant flow — Period 1
MilestoneTreatment Sequence ADBCTreatment Sequence BACDTreatment Sequence CBDATreatment Sequence DCAB
Started6666
Completed6666
Not completed0000
Period 2
Participant flow — Period 2
MilestoneTreatment Sequence ADBCTreatment Sequence BACDTreatment Sequence CBDATreatment Sequence DCAB
Started6666
Completed6666
Not completed0000
Period 3
Participant flow — Period 3
MilestoneTreatment Sequence ADBCTreatment Sequence BACDTreatment Sequence CBDATreatment Sequence DCAB
Started6666
Completed6566
Not completed0100
Withdrew: Adverse event0100
Period 4
Participant flow — Period 4
MilestoneTreatment Sequence ADBCTreatment Sequence BACDTreatment Sequence CBDATreatment Sequence DCAB
Started6566
Completed6566
Not completed0000

Outcome measures

PrimarySaxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Geometric mean · ng*hr/mL
Saxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])
ng*hr/mLTreatment ATreatment BTreatment CTreatment D
Saxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])49.23 ± 18.5249.94 ± 19.7252.50 ± 17.9553.15 ± 17.81
Statistical analysis
  • Treatment A vs Treatment B · Ratio (%) of geometric ls means: 101.45 · 90% CI 98.17 to 104.84Ratio=Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries. LS=Least Squares.
  • Treatment C vs Treatment D · Ratio (%) of geometric ls means: 102.43 · 90% CI 99.53 to 105.42Ratio=Treatment D/Treatment C. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment A · Geometric least squares mean (ng*hr/ml): 49.23
  • Treatment B · Geometric least squares mean (ng*hr/ml): 49.94
  • Treatment C · Geometric least squares mean (ng*hr/ml): 52.71
  • Treatment D · Geometric least squares mean (ng*hr/ml): 53.99
Secondary5-hydroxy Saxagliptin PK Parameter AUC(0-inf)

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Geometric mean · ng*hr/mL
5-hydroxy Saxagliptin PK Parameter AUC(0-inf)
ng*hr/mLTreatment ATreatment BTreatment CTreatment D
5-hydroxy Saxagliptin PK Parameter AUC(0-inf)118.58 ± 24.08119.54 ± 21.16121.99 ± 25.42125.54 ± 24.82
Secondary5-hydroxy Saxagliptin PK Parameter Cmax

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Geometric mean · ng/mL
5-hydroxy Saxagliptin PK Parameter Cmax
ng/mLTreatment ATreatment BTreatment CTreatment D
5-hydroxy Saxagliptin PK Parameter Cmax16.83 ± 32.9516.72 ± 32.9217.35 ± 32.9518.59 ± 30.78
PrimarySaxagliptin PK Parameter Observed Maximum Plasma Concentration (Cmax)

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Geometric mean · ng/mL
Saxagliptin PK Parameter Observed Maximum Plasma Concentration (Cmax)
ng/mLTreatment ATreatment BTreatment CTreatment D
Saxagliptin PK Parameter Observed Maximum Plasma Concentration (Cmax)9.73 ± 20.449.97 ± 29.0710.25 ± 26.8710.88 ± 23.72
Statistical analysis
  • Treatment A vs Treatment B · Ratio (%) of geometric ls means: 102.46 · 90% CI 94.68 to 110.88Ratio=Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment C vs Treatment D · Ratio (%) of geometric ls means: 106.24 · 90% CI 98.43 to 114.66Ratio=Treatment D/Treatment C. Geometric least squares means values presented in other statistical analysis entries.
  • Treatment A · Geometric least squares mean (ng/ml): 9.73
  • Treatment B · Geometric least squares mean (ng/ml): 9.97
  • Treatment C · Geometric least squares mean (ng/ml): 10.33
  • Treatment D · Geometric least squares mean (ng/ml): 10.97
PrimaryMetformin PK Parameter AUC(0-inf)

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Geometric mean · ng*hr/mL
Metformin PK Parameter AUC(0-inf)
ng*hr/mLTreatment ATreatment BTreatment CTreatment D
Metformin PK Parameter AUC(0-inf)11998.00 ± 23.6812271.61 ± 20.4211988.30 ± 16.9411838.11 ± 18.18
Statistical analysis
  • Treatment A vs Treatment B · Ratio (%) of geometric ls means: 102.10 · 90% CI 97.26 to 107.18Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment C vs Treatment D · Ratio (%) of geometric ls means: 99.17 · 90% CI 96.23 to 102.21Ratio=Treatment D/Treatment C. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment A · Geometric least squares mean (ng*hr/ml): 11998
  • Treatment B · Geometric least squares mean (ng*hr/ml): 12250
  • Treatment C · Geometric least squares mean (ng*hr/ml): 12036
  • Treatment D · Geometric least squares mean (ng*hr/ml): 11937
PrimaryMetformin PK Parameter Cmax

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Geometric mean · ng/mL
Metformin PK Parameter Cmax
ng/mLTreatment ATreatment BTreatment CTreatment D
Metformin PK Parameter Cmax1724.38 ± 25.491715.79 ± 23.591571.21 ± 15.641541.76 ± 17.45
Statistical analysis
  • Treatment A vs Treatment B · Ratio (%) of geometric ls means: 99.50 · 90% CI 90.41 to 109.5Ratio=Treatment B/Treatment A. Geometric least squares means values presented in other statistical analysis entries.
  • Treatment C vs Treatment D · Ratio (%) of geometric ls means: 98.22 · 90% CI 94.28 to 102.32Ratio=Treatment D/Treatment C. Geometric least squares means values presented in other statistical analysis entries.
  • Treatment A · Geometric least squares mean (ng/ml: 1724.4
  • Treatment B · Geometric least square means (ng/ml): 1715.8
  • Treatment C · Geometric least square mean (ng/ml): 1581.4
  • Treatment D · Geometric least squares mean (ng/ml): 1553.2
Secondary5-hydroxy Saxagliptin PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\[0-t\] is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Geometric mean · ng*hr/mL
5-hydroxy Saxagliptin PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])
ng*hr/mLTreatment ATreatment BTreatment CTreatment D
5-hydroxy Saxagliptin PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])109.60 ± 25.81110.61 ± 22.77113.15 ± 26.53117.04 ± 25.74
Secondary5-hydroxy Saxagliptin PK Parameter Terminal Half-life (T 1/2)

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Mean · hr
5-hydroxy Saxagliptin PK Parameter Terminal Half-life (T 1/2)
hrTreatment ATreatment BTreatment CTreatment D
5-hydroxy Saxagliptin PK Parameter Terminal Half-life (T 1/2)7.58 ± 1.327.58 ± 1.357.48 ± 1.107.22 ± 1.01
Secondary5-hydroxy Saxagliptin PK Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax)

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Mean · hr
5-hydroxy Saxagliptin PK Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax)
hrTreatment ATreatment BTreatment CTreatment D
5-hydroxy Saxagliptin PK Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax)2.21 ± 0.751.86 ± 0.712.65 ± 0.832.46 ± 0.72
SecondarySafety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs).

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

Time frame:
AEs: from study drug administration Day 1/Period 1 till study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or study participation. Duration of the study was approximately 45 days (including screening).
Reported as:
Number · participants
Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs).
participantsTreatment ATreatment BTreatment CTreatment D
Number of Participants With at Least 1 AE4534
Discontinuation Due to AE1000
Deaths0000
SAEs0000
Other pre-specifiedSaxagliptin PK Parameter AUC(0-t)

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-t) is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Geometric mean · ng*hr/mL
Saxagliptin PK Parameter AUC(0-t)
ng*hr/mLTreatment ATreatment BTreatment CTreatment D
Saxagliptin PK Parameter AUC(0-t)47.15 ± 17.9847.83 ± 19.7750.69 ± 17.7451.37 ± 17.63
Statistical analysis
  • Treatment A vs Treatment B · Ratio (%) of geometric ls means: 101.43 · 90% CI 98.07 to 104.90Ratio=Treatment B/Treatment A. Geometric least squares means values presented in other statistical analysis entries.
  • Treatment C vs Treatment D · Ratio (%) of geometric ls means: 102.52 · 90% CI 99.56 to 105.57Ratio=Treatment D/Treatment C. Geometric least squares means values presented in other statistical analysis entries.
  • Treatment A · Geometric least squares mean (ng*h/ml): 47.15Geometric least squares means for Treatment A.
  • Treatment B · Geometric least squares mean (ng*h/ml): 47.83Geometric least squares means for Treatment B.
  • Treatment C · Geometric least squares mean (ng*h/ml): 50.89Geometric least squares means for Treatment C.
  • Treatment D · Geometric least squares mean (ng*h/ml): 52.17Geometric least squares means for Treatment D.
Other pre-specifiedSaxagliptin PK Parameter T1/2

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Mean · hr
Saxagliptin PK Parameter T1/2
hrTreatment ATreatment BTreatment CTreatment D
Saxagliptin PK Parameter T1/26.45 ± 1.006.21 ± 1.255.86 ± 0.926.09 ± 0.94
Other pre-specifiedSaxagliptin PK Parameter Tmax

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Mean · hr
Saxagliptin PK Parameter Tmax
hrTreatment ATreatment BTreatment CTreatment D
Saxagliptin PK Parameter Tmax1.38 ± 0.790.96 ± 0.611.94 ± 0.951.48 ± 0.58
Other pre-specifiedMetformin PK Parameter AUC(0-t)

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-t) is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Geometric mean · ng*hr/mL
Metformin PK Parameter AUC(0-t)
ng*hr/mLTreatment ATreatment BTreatment CTreatment D
Metformin PK Parameter AUC(0-t)11826.52 ± 23.8611875.08 ± 21.4711796.60 ± 17.0311681.05 ± 17.59
Statistical analysis
  • Treatment A vs Treatment B · Ratio (%) of geometric ls means: 100.41 · 90% CI 95.40 to 105.68Ratio=Treatment B/Treatment A. Geometric least squares means values presented in other statistical analysis entries.
  • Treatment C vs Treatment D · Ratio (%) of geometric ls means: 99.06 · 90% CI 96.19 to 102.02Ratio=Treatment D/Treatment C. Geometric least squares means values presented in other statistical analysis entries.
  • Treatment A · Geometric least squares mean (ng*h/ml): 11827Geometric least squares means for Treatment A.
  • Treatment B · Geometric least squares mean (ng*h/ml): 11875Geometric least squares means for Treatment B.
  • Treatment C · Geometric least squares mean (ng*h/ml): 11845Geometric least squares means for Treatment C.
  • Treatment D · Geometric least squares mean (ng*h/ml): 11734Geometric least squares means for Treatment D.
Other pre-specifiedMetformin PK Parameter T1/2

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Mean · hr
Metformin PK Parameter T1/2
hrTreatment ATreatment BTreatment CTreatment D
Metformin PK Parameter T1/210.94 ± 4.1313.15 ± 6.6710.82 ± 3.1811.13 ± 3.08
Other pre-specifiedMetformin PK Parameter Tmax

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.

Time frame:
Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Reported as:
Mean · hr
Metformin PK Parameter Tmax
hrTreatment ATreatment BTreatment CTreatment D
Metformin PK Parameter Tmax2.41 ± 0.782.54 ± 0.923.74 ± 0.543.74 ± 0.45
SecondarySafety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities

Abnormalities that were considered clinically significant and/or reported as an AE by the investigator.

Time frame:
From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).
Reported as:
Number · participants
Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities
participantsTreatment ATreatment BTreatment CTreatment D
Clinical Laboratory Abnormalities0010
Vital Sign Abnormalities0000
Physical Examination Abnormalities0000
12-Lead ECG Abnormalities0000

Adverse events

Collected over AEs: from study drug administration Day 1/Period 1 till study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or study participation. Duration of the study was approximately 45 days (including screening).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A—0/24 (0%)4/24 (16.7%)
Treatment B—0/24 (0%)5/24 (20.8%)
Treatment C—0/23 (0%)3/23 (13%)
Treatment D—0/23 (0%)4/23 (17.4%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventTreatment ATreatment BTreatment CTreatment D
DiarrhoeaGastrointestinal disorders1/242/241/233/23
Abdominal painGastrointestinal disorders2/241/240/231/23
DizzinessNervous system disorders1/241/240/231/23
NasopharyngitisInfections and infestations0/240/241/230/23
FatigueGeneral disorders0/240/241/231/23
Vision blurredEye disorders0/241/240/230/23
HeadacheNervous system disorders1/240/240/230/23
PresyncopeNervous system disorders0/241/240/230/23
NauseaGastrointestinal disorders1/240/240/230/23
Muscle strainInjury, poisoning and procedural complications1/240/240/230/23

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Enrolled and Treated Participants
Mean35.5 ± 10.61
Sex: Female, Male
Sex: Female, Male(Participants)All Enrolled and Treated Participants
Female8
Male16
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Enrolled and Treated Participants
Hispanic or Latino11
Not Hispanic or Latino13
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Enrolled and Treated Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White21
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)All Enrolled and Treated Participants
United States24
Height
Height(cm)All Enrolled and Treated Participants
Mean170.2 ± 12.0
Weight
Weight(kg)All Enrolled and Treated Participants
Mean79.7 ± 13.7
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)All Enrolled and Treated Participants
Mean27.4 ± 3.05
08

Study locations

1 site
  • PPD Development, LP
    Austin, Texas 78744, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2010
First posted
Feb 15, 2010
Start
Feb 2010
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
Feb 8, 2012
Last update
May 8, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01068743
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 15, 2010
Start date
Feb 2010
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Feb 8, 2012
Last update
May 8, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Saxagliptin · Metformin

Start the discussion